The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer

Therapeutic Advances in Urology

Volumn 7, Issue 3, 2015, Pages 135-145

  Rose, Jim N ^a   Crook, Juanita M ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

bone metastases; hemi body radiotherapy; palliative radiotherapy; prostate cancer; radiopharmaceuticals; radium 223

Indexed keywords

RADIUM CHLORIDE RA 223; SAMARIUM 153; STRONTIUM 89;

BONE METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MALE; PRIORITY JOURNAL; REVIEW; SPINAL CORD COMPRESSION; TREATMENT INDICATION;

EID: 84930389259     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287215576647     Document Type: Review

References (111)

1. Ahmed K. Stauder M. Miller R. Bauer H. Rose P. Olivier K. (2012) Stereotactic body radiation therapy in spinal metastases. Int J Radiat Oncol Biol Phys 82: e803–e809.
2. Amdur R. Bennett J. Olivier K. Wallace A. Morris C. Liu C. (2009) A prospective, phase II study demonstrating the potential value and limitation of radiosurgery for spine metastases. Am J Clin Oncol 32: 515–520.
3. Bashir F. Parry J. Windsor P. (2008) Use of a modified hemi-body irradiation technique for metastatic carcinoma of the prostate: report of a 10-year experience. Clin Oncol (R Coll Radiol) 20: 591–598.
4. Ben-Josef E. Shamsa F. Williams A. Porter A. (1998) Radiotherapeutic management of osseous metastases: a survey of current patterns of care. Int J Radiat Oncol Biol Phys 40: 915–921.
5. Berg R. Yilmaz M. Hoyer M. Keldsen N. Nielsen O. Ewertz M. (2009) Half body irradiation of patients with multiple bone metastases: a phase II trial. Acta Oncol 48: 556–561.
6. Biersack H. Palmedo H. Andris A. Rogenhofer S. Knapp F. Guhlke S. (2011) Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med 52: 1721–1726.
7. Bone Pain Trial Working Party (1999) 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiother Oncol 52: 111–121.
8. Caravatta L. Padula G. Macchia G. Ferrandina G. Bonomo P. Deodato F. (2012) Short-course accelerated radiotherapy in palliative treatment of advanced pelvic malignancies: a phase I study. Int J Radiat Oncol Biol Phys 83: e627–e631.
9. Chang E. Shiu A. Mendel E. Mathews L. Mahajan A. Allen P. (2007) Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine 7: 151–160.
10. Chow E. Danjoux C. Wong R. Szumacher E. Franssen E. Fung K. (2000) Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists. Radiother Oncol 56: 305–314.
11. Chow E. Harris K. Fan G. Tsao M. Sze W. (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25: 1423–1436.
12. Chow E. Wu J. Loblaw A. Perez C. (2003) Radiotherapeutic approaches to metastatic disease. World J Urol 21: 229–242.
13. Collins C. Eary J. Donaldson G. Vernon C. Bush N. Petersdorf S. (1993) Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 34: 1839–1844.
14. Crain D. Amling C. Kane C. (2004) Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol 171: 668–671.
15. Dearnaley D. Bayly R. A–Hern R. Gadd J. Zivanovic M. Lewington V. (1992) Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89? Clin Oncol (R Coll Radiol) 4: 101–107.
16. Din O. Thanvi N. Ferguson C. Kirkbride P. (2009) Palliative prostate radiotherapy for symptomatic advanced prostate cancer. Radiother Oncol 93: 192–196.
17. Eary J. Collins C. Stabin M. Vernon C. Petersdorf S. Baker M. (1993) Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 34: 1031–1036.
18. Fairchild A. Barnes E. Ghosh S. Ben-Josef E. Roos D. Hartsell W. (2009) International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice? Int J Radiat Oncol Biol Phys 75: 1501–1510.
19. Fizazi K. Beuzeboc P. Lumbroso J. Haddad V. Massard C. Gross-Goupil M. (2009) Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27: 2429–2435.
20. Fossa S. (1987) Palliative pelvic radiotherapy in patients with hormone-resistant prostatic cancer. Prog Clin Biol Res 243B: 479–485.
21. Fossa S. Dearnaley D. Law M. Gad J. Newling D. Tveter K. (1992) Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol 3: 361–366.
22. Fryer C. Fitzpatrick P. Rider W. Poon P. (1978) Radiation pneumonitis: experience following a large single dose of radiation. Int J Radiat Oncol Biol Phys 4: 931–936.
23. Furuya Y. Akakura K. Akimoto S. Ichikawa T. Ito H. (1999) Radiotherapy for local progression in patients with hormone-refractory prostate cancer. Int J Urol 6: 187–191.
24. Garg A. Shiu A. Yang J. Wang X. Allen P. Brown B. (2012) Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases. Cancer 118: 5069–5077.
25. Gaze M. Kelly C. Kerr G. Cull A. Cowie V. Gregor A. (1997) Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. Radiother Oncol 45: 109–116.
26. Gilbert R. Kim J. Posner J. (1978) Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol 3: 40–51.
27. Gogna N. Baxi S. Hickey B. Baumann K. Burmeister E. Holt T. (2012) Split-course, high-dose palliative pelvic radiotherapy for locally progressive hormone-refractory prostate cancer. Int J Radiat Oncol Biol Phys 83: e205–e211.
28. Haley M. Gerszten P. Heron D. Chang Y. Atteberry D. Burton S. (2011) Efficacy and cost-effectiveness analysis of external beam and stereotactic body radiation therapy in the treatment of spine metastases: a matched-pair analysis. J Neurosurg Spine 14: 537–542.
29. Hartsell W. Scott C. Bruner D. Scarantino C. Ivker R. Roach M. (2005) Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97: 798–804.
30. Hellerstedt B. Pienta K. (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52: 154–179.
31. Hernes E. Linja M. Fossa S. Visakorpi T. Berner A. Winderen M. (2000) Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors. BJU Int 86: 240–247.
32. Hindson B. Turner S. Do V. (2007) Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancer. Australas Radiol 51: 584–588.
33. Hoskin P. Ford H. Harmer C. (1989) Hemibody irradiation (HBI) for metastatic bone pain in two histologically distinct groups of patients. Clin Oncol (R Coll Radiol) 1: 67–69.
34. Hoskin P. Price P. Easton D. Regan J. Austin D. Palmer S. (1992) A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 23: 74–78.
35. Huisman M. van den Bosch M. Wijlemans J. van Vulpen M. van der Linden Y. Verkooijen H. (2012) Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 84: 8–14.
36. Husband D. (1998) Malignant spinal cord compression: prospective study of delays in referral and treatment. BMJ 317: 18–21.
37. Hussain M. Tangen C. Berry D. Higano C. Crawford E. Liu G. (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368: 1314–1325.
38. James N. Pirrie S. Barton D. Brown J. Billingham L. Collins S. (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). J Clin Oncol 31: abstract LBA5000.
39. Jeremic B. Shibamoto Y. Acimovic L. Milicic B. Milisavljevic S. Nikolic N. (1998) A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int J Radiat Oncol Biol Phys 42: 161–167.
40. Kamat A. Huang S. Bermejo C. Rosser C. Pettaway C. Pisters P. (2003) Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170: 1868–1871.
41. Koch M. De Keyser J. (2006) Surgical resection in metastatic spinal cord compression. Lancet 367: 109
42. Konski A. (2004) Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. Int J Radiat Oncol Biol Phys 60: 1373–1378.
43. Kraeber-Bodere F. Campion L. Rousseau C. Bourdin S. Chatal J. Resche I. (2000) Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 27: 1487–1493.
44. Lam M. Dahmane A. Stevens W. van Rijk P. de Klerk J. Zonnenberg B. (2008) Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 35: 756–765.
45. Lankford S. Pollack A. Zagars G. (1995) Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys 33: 907–912.
46. Lee C. Aeppli D. Unger J. Boudreau R. Levitt S. (1996) Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience. Am J Clin Oncol 19: 102–107.
47. Lee S. Chun M. (2012) Pain relief by Cyberknife radiosurgery for spinal metastasis. Tumori 98: 238–242.
48. Lewington V. McEwan A. Ackery D. Bayly R. Keeling D. Macleod P. (1991) A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 27: 954–958.
49. Liepe K. Kropp J. Runge R. Kotzerke J. (2003) Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 89: 625–629.
50. Lin J. Sinibaldi V. Carducci M. Denmeade S. Song D. Deweese T. (2011) Phase I trial with a combination of docetaxel and (1)(5)(3)Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol 29: 670–675.
51. Loblaw D. Mitera G. Ford M. Laperriere N. (2012) A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. Int J Radiat Oncol Biol Phys 84: 312–317.
52. Loblaw D. Perry J. Chambers A. Laperriere N. (2005) Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative–s Neuro-Oncology Disease Site Group. J Clin Oncol 23: 2028–2037.
53. Lutz S. Chow E. Hartsell W. Konski A. (2007) A review of hypofractionated palliative radiotherapy. Cancer 109: 1462–1470.
54. Maranzano E. Bellavita R. Rossi R. De Angelis V. Frattegiani A. Bagnoli R. (2005) Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol 23: 3358–3365.
55. Maranzano E. Latini P. (1995) Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys 32: 959–967.
56. Maranzano E. Latini P. Beneventi S. Perruci E. Panizza B. Aristei C. (1996) Radiotherapy without steroids in selected metastatic spinal cord compression patients. A phase II trial. Am J Clin Oncol 19: 179–183.
57. Maranzano E. Latini P. Perrucci E. Beneventi S. Lupattelli M. Corgna E. (1997) Short-course radiotherapy (8 Gy x 2) in metastatic spinal cord compression: an effective and feasible treatment. Int J Radiat Oncol Biol Phys 38: 1037–1044.
58. Maxon H. Schroder L. Thomas S. Hertzberg V. Deutsch E. Scher H. (1990) Re-186(sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 176: 155–159.
59. Megalli M. Gursel E. Demirag H. Veenema R. Guttman R. (1974) External radiotherapy in ureteral obstruction secondary to locally invasive prostatic cancer. Urology 3: 562–564.
60. Morris M. Pandit-Taskar N. Carrasquillo J. Divgi C. Slovin S. Kelly W. (2009) Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 27: 2436–2442.
61. Nelson J. Yoo D. Sampson J. Isaacs R. Larrier N. Marks L. (2009) Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. Int J Radiat Oncol Biol Phys 73: 1369–1375.
62. Nielsen O. Bentzen S. Sandberg E. Gadeberg C. Timothy A. (1998) Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 47: 233–240.
63. Niewald M. Tkocz H. Abel U. Scheib T. Walter K. Nieder C. (1996) Rapid course radiation therapy vs. more standard treatment: a randomized trial for bone metastases. Int J Radiat Oncol Biol Phys 36: 1085–1089.
64. Nilsson S. Franzen L. Parker C. Tyrrell C. Blom R. Tennvall J. (2013) Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 11: 20–26.
65. Nilsson S. Larsen R. Fossa S. Balteskard L. Borch K. Westlin J. (2005) First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11: 4451–4459.
66. Oosterhof G. Roberts J. de Reijke T. Engelholm S. Horenblas S. von der Maase H. (2003) Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 44: 519–526.
67. Otnes B. Harvei S. Fossa S. (1995) The burden of prostate cancer from diagnosis until death. Br J Urol 76: 587–594.
68. Palmedo H. Manka-Waluch A. Albers P. Schmidt-Wolf I. Reinhardt M. Ezziddin S. (2003) Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21: 2869–2875.
69. Parker C. Nilsson S. Heinrich D. Helle S. O–Sullivan J. Fossa S. (2013a) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369: 213–223.
70. Parker C. Pascoe S. Chodacki A. O–Sullivan J. Germa J. O–Bryan-Tear C. (2013b) A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 63: 189–197.
71. Patchell R. Tibbs P. Regine W. Payne R. Saris S. Kryscio R. (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366: 643–648.
72. Pons F. Herranz R. Garcia A. Vidal-Sicart S. Conill C. Grau J. (1997) Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 24: 1210–1214.
73. Porter A. McEwan A. Powe J. Reid R. McGowan D. Lukka H. (1993) Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25: 805–813.
74. Poulter C. Cosmatos D. Rubin P. Urtasun R. Cooper J. Kuske R. (1992) A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. Int J Radiat Oncol Biol Phys 23: 207–214.
75. Price P. Hoskin P. Easton D. Austin D. Palmer S. Yarnold J. (1986) Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 6: 247–255.
76. Priestman T. Roberts J. Lucraft H. Collis C. Adams M. Upadhyaya B. (1990) Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol (R Coll Radiol) 2: 71–75.
77. Quilty P. Kirk D. Bolger J. Dearnaley D. Lewington V. Mason M. (1994) A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31: 33–40.
78. Rades D. Fehlauer F. Stalpers L. Wildfang I. Zschenker O. Schild S. (2004) A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression: final results of a multicenter study. Cancer 101: 2687–2692.
79. Rades D. Huttenlocher S. Dunst J. Bajrovic A. Karstens J. Rudat V. (2010) Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. J Clin Oncol 28: 3597–3604.
80. Resche I. Chatal J. Pecking A. Ell P. Duchesne G. Rubens R. (1997) A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33: 1583–1591.
81. Robinson R. Preston D. Schiefelbein M. Baxter K. (1995) Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 274: 420–424.
82. Ross R. Xie W. Regan M. Pomerantz M. Nakabayashi M. Daskivich T. (2008) Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 112: 1247–1253.
83. Sahgal A. Ames C. Chou D. Ma L. Huang K. Xu W. (2009) Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases. Int J Radiat Oncol Biol Phys 74: 723–731.
84. Sahgal A. Roberge D. Schellenberg D. Purdie T. Swaminath A. Pantarotto J. (2012) The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. Clin Oncol (R. Coll. Radiol) 24: 629–639.
85. Salazar O. DaMotta N. Bridgman S. Cardiges N. Slawson R. (1996) Fractionated half-body irradiation for pain palliation in widely metastatic cancers: comparison with single dose. Int J Radiat Oncol Biol Phys 36: 49–60.
86. Salazar O. Rubin P. Hendrickson F. Komaki R. Poulter C. Newall J. (1986) Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report. Cancer 58: 29–36.
87. Salazar O. Rubin P. Keller B. Scarantino C. (1978) Systemic (half-body) radiation therapy: response and toxicity. Int J Radiat Oncol Biol Phys 4: 937–950.
88. Salazar O. Sandhu T. da Motta N. Escutia M. Lanzos-Gonzales E. Mouelle-Sone A. (2001) Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys 50: 765–775.
89. Sartor O. Reid R. Hoskin P. Quick D. Ell P. Coleman R. (2004) Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63: 940–945.
90. Schiff D. Shaw E. Cascino T. (1995) Outcome after spinal reirradiation for malignant epidural spinal cord compression. Ann Neurol 37: 583–589.
91. Sciuto R. Festa A. Rea S. Pasqualoni R. Bergomi S. Petrilli G. (2002) Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 43: 79–86.
92. Serafini A. Houston S. Resche I. Quick D. Grund F. Ell P. (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16: 1574–1581.
93. Smeland S. Erikstein B. Aas M. Skovlund E. Hess S. Fossa S. (2003) Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 56: 1397–1404.
94. Sorensen S. Borgesen S. Rohde K. Rasmusson B. Bach F. Boge-Rasmussen T. (1990) Metastatic epidural spinal cord compression. Results of treatment and survival. Cancer 65: 1502–1508.
95. Spanos W. Jr Perez C. Marcus S. Poulter C. Doggett R. Steinfeld A. (1993) Effect of rest interval on tumor and normal tissue response – a report of phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG-8502). Int J Radiat Oncol Biol Phys 25: 399–403.
96. Spanos W. Jr Wasserman T. Meoz R. Sala J. Kong J. Stetz J. (1987) Palliation of advanced pelvic malignant disease with large fraction pelvic radiation and misonidazole: final report of RTOG phase I/II study. Int J Radiat Oncol Biol Phys 13: 1479–1482.
97. Steenland E. Leer J. van Houwelingen H. Post W. van den Hout W. Kievit J. (1999) The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 52: 101–109.
98. Suttmann H. Grgic A. Lehmann J. Zwergel U. Kamradt J. Gouverneur E. (2008) Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience. Cancer Biother Radiopharm 23: 609–618.
99. Taylor C. Elson P. Trump D. (1993) Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11: 2167–2172.
100. Tian J. Zhang J. Hou Q. Oyang Q. Wang J. Luan Z. (1999) Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 26: 2–7.
101. Townsend P. Rosenthal H. Smalley S. Cozad S. Hassanein R. (1994) Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease. J Clin Oncol 12: 2345–2350.
102. Tu S. Mathew P. Wong F. Jones D. Johnson M. Logothetis C. (2009) Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol 27: 3319–3324.
103. Tu S. Millikan R. Mengistu B. Delpassand E. Amato R. Pagliaro L. (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357: 336–341.
104. Turner S. Gruenewald S. Spry N. Gebski V. and Metastron Users Group (2001) Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 84: 297–302.
105. van den Hout W. van der Linden Y. Steenland E. Wiggenraad R. Kievit J. de Haes H. (2003) Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 95: 222–229.
106. Van Dyk J. Keane T. Kan S. Rider W. Fryer C. (1981) Radiation pneumonitis following large single dose irradiation: a re-evaluation based on absolute dose to lung. Int J Radiat Oncol Biol Phys 7: 461–467.
107. Wang X. Rhines L. Shiu A. Yang J. Selek U. Gning I. (2012) Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial. Lancet Oncol 13: 395–402.
108. Windsor P. (2001) Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre–s 10-year experience. Clin Oncol (R Coll Radiol) 13: 219–227.
109. Young R. Post E. King G. (1980) Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy. J Neurosurg 53: 741–748.
110. Zelefsky M. Scher H. Forman J. Linares L. Curley T. Fuks Z. (1989) Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens. Int J Radiat Oncol Biol Phys 17: 1281–1285.
111. Zelefsky M. Scher H. Krol G. Portenoy R. Leibel S. Fuks Z. (1992) Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy. Cancer 70: 2319–2325.